Novanta Inc. (NOVT)
被高估基本面
55
价格
$143.99
市值
$5.38B
第一部分 · 这家公司值多少
概览
Novanta Inc., together with its subsidiaries, provides precision medicine, precision manufacturing, medical solutions, robotics and automation solutions, and advanced surgery solutions in the United States and internationally. The company operates Automation Enabling Technologies and Medical Solutions segments. The Precision Medicine and Manufacturing segment designs, manufactures, and markets laser beam steering and scanning solutions, laser sources, robotic and precision motion, robotic end-of-arm tooling, and bearing spindles. This segment serves advanced industrial processes, advanced industrial and medical robotics, other medical and life science automation applications, and medical laser procedures, such as ophthalmology applications. The Medical Solutions segment provides a range of medical grade technologies, including medical insufflators, pumps, and related disposables; imaging, identification and RFID solutions; advanced motion control solutions; and light engines, and integrated operating room technologies. The company was formerly known as GSI Group, Inc. and changed its name to Novanta Inc. in May 2016. Novanta Inc. was incorporated in 1968 and is based in Bedford, Massachusetts.
No editorial profile for this company yet
Direct competitors
Who this company fights with for the same customers
Generated on 2026年9月19日 with claude-haiku-4-5 — shared with all users
Named by Novanta as a major Photonics competitor: it supplies the same OEM customers with laser sources, optics and beam-delivery subsystems for industrial processing and medical devices.
Named by Novanta as a major Photonics competitor: both sell galvanometer-based laser beam-steering scan heads to the same industrial and medical laser-system builders.
Novanta names Omron Microscan Systems as a major Vision competitor: the two compete for the same factory-automation and medical-device OEMs buying machine vision and barcode reading subsystems.
Named by Novanta as a major Precision Motion competitor: both sell optical encoders and precision position-feedback devices to machine-tool, semiconductor and medical equipment makers.
Named by Novanta as a major Vision competitor: Barco's healthcare visualization business competes directly with Novanta's surgical and diagnostic display systems sold to medical OEMs and hospitals.
Named by Novanta as a major Precision Motion competitor: both supply precision positioning stages and motion subsystems to the same photonics, semiconductor and life-science instrument builders.
资产负债表与流动性
营收
$1.03B
最近12个月(截至2026/7/3)
净利润
$62M
最近12个月(截至2026/7/3)
自由现金流
$48M
股东权益合计
$1.31B
负债合计
$493M
流动比率
4.57
利息覆盖率
-
债务/EBITDA
1.83
每股收益
营收与净利润
自由现金流
收入构成
历史财务表
利润率变化
债务变化
债务负担有多重
增长一览表
增长 — 营业收入
公允价值估算
公允价值
$89.83
当前价格
$143.99
安全边际
-60.3%
公允价值区间
$58.39 - $121.27
所用估值方法之间的离散区间,并非经过统计校准的置信区间。
估算方法
估值指标
市盈率(P/E)
90.57
ROE
4.1%
市净率(P/B)
3.33
P/FCF
47.05
毛利率
44.5%
ROIC
3.9%
盈利能力雷达图
价值创造(经济护城河)
ROIC
3.9%
WACC
13.3%
ROIC − WACC
-9.5 pp
ROIC 低于资本成本:公司每投入一美元都在毁灭价值。
基本面分析标准
通过(16)
- EPS shows upward trend
- Price CAGR 21.27%
- Gross Margin 44.5%
- Debt/Equity ratio
- Operating Margin 9.0%
- Positive Free Cash Flow
- CapEx intensity
- Current Ratio
- Debt/EBITDA
- Return on Tangible Assets
- Revenue Growth 5Y 10.7%
- Analyst Consensus 89% Buy
- Earnings Surprise avg 3.3%
- Earnings Quality (OCF/NI) 2.17
- Share Dilution 1.1%
- Piotroski F-Score 5/9
未通过(9)
- ROIC 3.8%
- P/FCF 47.05
- P/B Ratio 3.33
- Low reliance on intangibles
- Price below Graham Number
- DCF valuation (Overvalued)
- ROE 4.9%
- PEG Ratio 26.26
- Net Margin Trend 6.0% vs 6.4%
不可用(2)
- Dividend Payout NaN%
- Interest Coverage
Piotroski F-评分
信号混杂:部分领域需关注
盈利质量
高质量:盈利有现金流支撑
股权稀释
股份数量稳定
机构持股
公司治理
管理团队
| 姓名 | 职位 | 年龄 |
|---|---|---|
| Mr. Matthijs Glastra | CEO & Chairman of the Board | 56 |
| Mr. Robert J. Buckley | Chief Financial Officer | 51 |
| Mr. Alexander Manganiello | General Counsel & Corporate Secretary | 58 |
| Mr. Charles G. Ravetto | Co-Chief Operating Officer of Automation Enabling Technologies | 54 |
| Mr. John Lesica | Co-Chief Operating Officer of Medical Solutions | 49 |
| Mr. John Joseph Burke II | Chief Accounting Officer & Corporate Controller | 43 |
| Ms. Sarah Betadam | Chief Information Officer & Chief Information Security Officer | - |
| Ms. Nissia Sabri | Senior Vice President of Corporate Development | - |
| Mr. Liam Weston | Chief Human Resources Officer | - |
| Mr. Heinrich Dreyer | Group President of Medical Solutions | - |
审计风险
2
董事会风险
4
薪酬风险
4
股东权利风险
2
第二部分 · 价格与买入时机
这一部分不判断公司是否值得拥有:它帮助你在基本面说服你之后,选择何时买入。包含:技术分析、潜力、历史回撤、Gamma 敞口。
损益历史
via SEC EDGAR
Latest News
Recent headlines for NOVT, sourced from Markets Gazette.
- 3/4/2026POSITIVENovanta Stock Has Underperformed This Past Year, but One Investor Just Made a $36 Million Bet on Shares
Despite underperforming over the past year, Novanta Inc. (NOVT) has attracted a significant bet from an investor who purchased $36 million worth of shares. This bold move suggests strong conviction in the company's future recovery and growth potential. Novanta designs photonics and precision motion solutions for OEMs in medical and industrial markets globally. While the stock has lagged, this substantial investment could signal a turning point, indicating that the company's underlying value is underestimated by the market and may lead to a positive re-evaluation.
- 2/24/2026NEUTRALNovanta (NOVT) Q4 2025 Earnings Call Transcript
Markets Gazette notes the release of the earnings call transcript for Novanta Inc. (NOVT) concerning its fourth-quarter 2025 results. While specific financial figures and future projections have not yet been made public or analyzed herein, the availability of this document is a key event for investors. Earnings call transcripts provide direct insights into company performance, management strategies, challenges faced, and growth prospects, often revealing the tone and expectations of leadership. Shareholders and analysts will closely monitor this document for any implicit or explicit signals that could influence the stock's value in the short to medium term. The current lack of specific content necessitates a cautious approach, but the transcript remains a crucial resource for due diligence.
- 2/23/2026NEUTRALA Preview Of Novanta's Earnings
The Markets Gazette notes that investor focus is turning to Novanta Inc. ahead of its upcoming earnings release. The article, while providing no specific data, serves as a calendar marker for a key event that could define the stock's short-term trajectory. Analysts and the market are awaiting crucial figures such as revenue, earnings per share (EPS), and, most importantly, forward-looking guidance for the coming quarters. The stock's reaction will largely depend on how the actual results compare against consensus estimates. Until the official announcement, traders are likely to maintain a cautious stance, with trading volumes potentially increasing closer to the release date, signaling heightened anticipation.
- 2/22/2026NEGATIVEIs Novanta Stock a Buy or Sell After Its CEO Dumped 6,500 Shares?
Novanta Inc., a leader in photonics and precision motion solutions for OEMs, has experienced notable insider selling. The CEO recently offloaded 6,500 shares, a move that could signal diminished confidence in the company's future performance from top management. While Novanta operates in promising tech sectors, this insider action might concern investors, suggesting the current stock price could be considered high or that potential challenges lie ahead not yet fully reflected in the market. Investors should closely watch upcoming financial reports and operational performance to assess the impact of this sale.
via Markets Gazette